Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Dujardin, Karl
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)	Recruiting	3	12500	Europe, Canada, Japan, US, RoW	Lepodisiran Sodium, LY3819469, Placebo	Eli Lilly and Company	Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a)	03/29	03/29
COL BE PCI, NCT06095765: Colchicine in Belgium in Patients With Coronary Artery Disease After Percutaneous Coronary Intervention	Recruiting	3	2770	Europe	Colchicine 0.5 MG Oral Tablet, Placebo	AZ Sint-Jan AV, University Hospital, Ghent, Belgium Health Care Knowledge Centre	Coronary Artery Disease	11/27	03/28
AMEND-CRT, NCT04225520: Mechanical Dyssynchrony as Selection Criterion for CRT	Recruiting	N/A	700	Europe, RoW	Cardiac resynchronization therapy ON, Cardiac resynchronization therapy OFF	Universitaire Ziekenhuizen KU Leuven	Left Ventricular Dyssynchrony, Heart Failure, Cardiomyopathy, Dilated, Cardiac Remodeling, Ventricular	12/25	12/30